Statistics show that HER-2 positive breast cancer is among the most aggressive subtypes and is responsible for approximately 30% of diagnosed cases, being associated with tumor invasiveness, low disease-free survival, and bad overall prognosis. This evidence concerns the gene ERBB2 and breast cancer.